International
Global delivery of care
Mayo Clinic Laboratories strives to ensure all patients around the world have access to the most advanced clinical diagnostic testing. Working with hospitals and health care providers worldwide, we deliver unparalleled expertise and the latest in diagnostic testing to deliver answers and improve outcomes for their patients.
Highlights
Join us for Mayo Clinic Laboratories Education first-ever virtual phlebotomy workshop on Wednesday, Oct. 1.
PACE/State of FL - Register now – Sept. 10, 2025
Clinically relevant overview of key genetic factors, testing strategies, and post-result care.
Conflict is a natural part of human interaction, and the workplace is not immune from that experience. Through this microlearning, we'll explore how proper conflict[...]
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, share insights from industry news and recent conferences, including PlatforMed.
For healthcare professionals seeking to enhance their understanding of the assessment and treatment options for patients with neurodegenerative diseases.
The increased prevalence of certain tick- and mosquito-borne illnesses, the benefits of an algorithmic testing approach, and the growing importance of co-infection testing.
On Tuesday, June 24, the mayocliniclabs.com website will feature a refreshed homepage. Incorporating valuable feedback from users, the site has been redesigned it to highlight the most frequently used features and content. The aim to enhance user experience with a more intuitive, visually appealing, and responsive website. These new features will make it easier to find information and complete tasks.
John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test can detect antihypertensive medications in urine, providing evidence of whether patients are actually absorbing their medications or whether a new approach might be needed.
Mayo Clinic Laboratories’ newly expanded Hereditary Pancreatitis Gene Panel is transforming how clinicians diagnose and manage a complex, often elusive disease. Developed through close collaboration between lab scientists, genetic counselors, and clinicians, the test uses a whole exome sequencing backbone to analyze nine carefully selected genes with strong clinical relevance. This focused approach avoids ambiguous results while empowering early diagnosis, cancer risk assessment, and family testing. Built on a whole exome backbone with reflex capabilities, the panel represents a major step forward in precision medicine — offering clarity for patients and providers, and a platform for future genomic innovation.
When introducing a new initiative in the medical laboratory environment, effective change management is essential.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Div Dubey, M.B.B.S., a neurologist and co-director of the Clinical Neuroimmunology Laboratory at Mayo Clinic, explore the topic of peripheral neuropathy.